Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment

Androgen receptor (AR) antagonists, such as enzalutamide, have had a major impact on the treatment of metastatic castration-resistant prostate cancer (CRPC). However, even with the advent of AR antagonist therapies, patients continue to develop resistance, and new strategies to combat continued AR s...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neoplasia
Asıl Yazarlar: Kregel, Steven, Wang, Chao, Han, Xin, Xiao, Lanbo, Fernandez-Salas, Ester, Bawa, Pushpinder, McCollum, Brooke L., Wilder-Romans, Kari, Apel, Ingrid J., Cao, Xuhong, Speers, Corey, Wang, Shaomeng, Chinnaiyan, Arul M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Neoplasia Press 2020
Konular:
Original article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6957805/
https://ncbi.nlm.nih.gov/pubmed/31931431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2019.12.003
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller